RCM
CEROW

Radcliffe Capital Management’s CERo Therapeutics Warrants CEROW Stock Holding History

Radcliffe Capital Management’s Portfolio CEROW Stock Details CEROW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-149,380
Closed -$4.11K – 87
2023
Q4 		$4.11K Sell
149,380
-620
-0.4% -$19 ﹤0.01% 153
2023
Q3 		$11.5K Hold
150,000
– – ﹤0.01% 331
2023
Q2 		$9.82K Hold
150,000
– – ﹤0.01% 419
2023
Q1 		$6.01K Hold
150,000
– – ﹤0.01% 601
2022
Q4 		$1.54M Hold
150,000
– – 0.05% 547
2022
Q3 		$1.51M Hold
150,000
– – 0.04% 761
2022
Q2 		$1.5M Hold
150,000
– – 0.03% 796
2022
Q1 		$1.5M Hold
150,000
– – 0.03% 777
2021
Q4 		$1.49M Buy
+150,000
New +$69.2K 0.04% 677

Other funds holding CEROW

HCM
Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.27% 1-Year Est. Return
ACM
Atalaya Capital Management New York $45M AUM 3.02% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 28.97% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 76.63% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
CSD
Clear Street Derivatives New York $12.4M AUM 1.7% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.57% 1-Year Est. Return

Radcliffe Capital Management's CEROW Position: Q1 2024 in Review

Radcliffe Capital Management sold out of CERo Therapeutics Warrants (CEROW) in Q1 2024, closing a stake of 149,380 shares — an estimated $4.11K sold.

Radcliffe Capital Management first reported a position in CEROW in Q4 2021 and held it in 9 quarters. The position peaked at $1.54M in Q4 2022. 37 funds tracked by Wall St. Rank hold CEROW as of Q1 2024.

  • Radcliffe Capital Management reported no remaining CERo Therapeutics Warrants position as of Q1 2024 after selling out during the quarter.
  • Radcliffe Capital Management sold 149,380 CERo Therapeutics Warrants shares in Q1 2024, an estimated $4.11K.
  • Radcliffe Capital Management first reported a position in CERo Therapeutics Warrants in Q4 2021 and held it in 9 quarters.
  • Radcliffe Capital Management's CERo Therapeutics Warrants position peaked at $1.54M in Q4 2022.
  • 37 funds tracked by Wall St. Rank held CERo Therapeutics Warrants as of Q1 2024.

Based on Radcliffe Capital Management's 13F filing for Q1 2024, filed 15 May 2024.